Abstract
Background/Aim: The enzyme-linked immunospot (ELISPOT) assay is a well-established method used to evaluate the strength of T cell-mediated immune activity, and accepted as a standard functional immunological assay. Cytokine activity is a novel parameter reflecting spot size and intensity, which has not been used in ELISPOT assay before. Materials and Methods: In the present study, from 113 ELISPOT assay data derived from previous clinical trials with dendritic cell vaccines, both spot number count and cytokine activity data for IFN-γ secretion were obtained using an ELISPOT reader. Comparing the new parameter cytokine activity with the existing parameter spot number, the feasibility of cytokine activity was investigated. Results: There were no significant differences in sensitivity and specificity between spot number and cytokine activity among ELISPOT assay data from CMVpp65 and other antigen peptide-stimulated cytotoxic T lymphocytes. Conclusion: Although cytokine activity is a novel parameter unreported so far, it did not show any advantages in the evaluation T cell immune responses compared to the existing spot number parameter.
- ELISPOT assay
- spot number
- cytokine activity
- ELISPOT reader
- HLA.
The enzyme-linked immunospot assay (ELISPOT) was first reported by Czerkinsky et al., and is available worldwide as a functional immunological assay for single-cell analysis (1, 2). Because of the easy establishment and performance of the assay system and high assay sensitivity, ELISPOT assays have been widely applied, ranging from laboratory experiments using animal models to clinical translational research, and multiple cytokine-secreting clonal T cells can be enumerated on a single-cell basis (3-8).
In contrast to the worldwide availability, the high grade of discrepancy and variability in ELISPOT measurement results among different laboratories has been a major challenge to medical immunologists and oncologists involved in clinical immunotherapy (9, 10). Generally, there are two major reasons responsible for the high grade of variability in ELISPOT results: the first is the difference in experimental protocols and instruments, and the second is the differences in data analysis methods.
To address this variability, a large-scale immune monitoring harmonization process, which was conducted by the Cancer Vaccine Consortium of the Sabin Vaccine Institute (CVC/SVI), was successfully performed through an external validation program. Janetzki et al. reported harmonization guidelines in 2008, which demonstrated a significant improvement in ELISPOT assay performance (11, 12).
Furthermore, there are three main parameters, spot number, spot size, and spot intensity used to analyze ELISPOT assay results. Regularly, spot number seems to be a standard parameter for evaluating the immune response (13-15); however, spot size and intensity parameters are sometimes helpful (16). Cytokine activity is a specific parameter that can be calculated from spot size and intensity values using the formula shown in Figure 1 and is available on an Autoimmun Diagnostika (AID) ELISPOT reader (17). However, cytokine activity has not been reported in the past literature.
In the current study, we focused on the cytokine activity parameter, comparing this parameter with the spot number counted on an AID system; eventually, the feasibility of the cytokine activity parameter was investigated.
Materials and Methods
Cancer patients enrolled in dendritic cell vaccine clinical trials. Twenty cancer patients (6 melanoma patients and 14 glioblastoma patients) were enrolled in dendritic cell (DC)-vaccine-based clinical trials and evaluated with ELISPOT assays (Table I). The HLA-A2-and A24-positive case numbers were 4 and 16, respectively. Peripheral blood mononuclear cells (PBMCs) from these patients were utilized for cytotoxic T lymphocyte (CTL) production assays with stimulation by HLA-A2- or HLA-A24-restricted CMVpp65 epitope or other peptide and eventually IFN-γ-associated spots were analyzed on an ELISPOT reader. Seventy-nine and 34 ELISPOT assays from CMVpp65- and other peptide-stimulated CTLs, respectively were given assay ID numbers and all results were investigated in the present study. In another experiment, the amount of IFN-γ secreted by cultured CTLs stimulated with CMVpp65 peptides was measured using ELISA.
ELISPOT assay. The ELISPOT assay was performed using PBMCs drawn prior to vaccination and after 4 DC injections, and the human IFN-γ ELISpot BASIC kit (3420-2A, MABTECH AB, Nacka, Sweden) was used as described previously (18, 19). Briefly, on day 1, HLA-A2- or HLA-A24-restricted CMVpp65 or other peptides were added to PBMCs in a 24-well culture plate and incubated in the presence of IL-2 and IL-7 for one week. On day 7, nonadherent cells were stimulated with adherent cells treated with CMVpp65 or other peptides again. On day 14, the responder cells were stimulated overnight with each peptide in a polyvinylidene fluoride (PVDF) plate coated with an anti-IFN-γ antibody (MultiScreen, MAIPS4510, Merck Millipore, Burlington, MA, USA). Finally, the positive spots stained with the anti-IFN-γ antibody were measured using an AID ELISPOT reader (Autoimmun Diagnostika GmbH, Strassberg, Germany).
Specifically, according to the manufacturer’s instructions, appropriate measurement conditions were set up as follows: spot count setting with a minimum intensity of 20, minimum gradient of 1.0 and minimum size of 30. The formula for calculating the cytokine activity parameter using spot size and intensity values is shown in Figure 1.
CTL induction cultures. PBMCs from melanoma patients and glioma patients were used for in vitro CTL induction (Clinical research using PBMCs and tumor tissues from cancer patients was approved by the Institutional Review Board of Shizuoka Cancer Center, Shizuoka, Japan). All patients gave written informed consent. The method of CTL induction cultures has been previously described (20).
IFN-γ production assay. T2 cells or TISI cells (20) were incubated overnight with the HLA-A2- or HLA-A24-restricted CMVpp65 peptide at 20 μg/ml, suspended in PBS (+) containing 1% human serum albumin (HSA), and prepared as target cells. Cultured CTLs (1×105) and CMVpp65 peptide-pulsed TISI cells (1×105) were co-incubated in a 96-well round-bottomed microculture plate for 24 h. Finally, the supernatants were collected and IFN-γ levels were measured using Human IFN-γ ELISA MAX™ Standard (BioLegend, San Diego, CA, USA).
Statistical analysis. To test the log-normal distribution of spot numbers and cytokine activity calculated from spot sizes and intensity values, the Kolmogorov-Smirnov fit test was performed using the freely available EZR software (21) and Microsoft Excel. The relationship between spot number and cytokine activity values of triplicate samples was analyzed using the Pearson coefficient test. The significance of differences between unstimulated and stimulated T cell responses generated with the CMVpp65 or other peptides in terms of ELISPOT number, cytokine activity or IFN-γ production level was evaluated using a paired two-tailed Student’s t-test. Values of p<0.05 were considered to be indicative of statistical significance.
Results
Spot number and cytokine activity parameters follow a log-normal distribution. The spot size and cytokine activity distributions of 43 positive ELISPOT result datasets from CMVpp65-stimulated CTLs were established. The normality of the spot number and cytokine activity distributions was tested using the Kolmogorov-Smirnov fit test. As a result, spot number and cytokine activity parameters followed a log-normal distribution (Figure 2A and B).
Relationship between any two parameters among spot number, cytokine activity and IFN-γ production level. The relationship between any two parameters was investigated using the Pearson coefficient test. The spot number count and cytokine activity showed a very strong positive relationship (r=0.963) (Figure 3A). Furthermore, there were eight cases in which spot number, cytokine activity, and IFN-γ production data were obtained from ELISPOT assays and CTL cultures stimulated with CMVpp65 peptides (Table II). Comparing spot number and cytokine activity with IFN-γ levels, it was revealed that these two parameters showed moderately positive relationships with IFN-γ production levels (Figure 3B).
Comparison between spot number and cytokine activity in terms of T cell responses to CMVpp65 or other peptides in an ELISPOT assay. Seventy-nine assays consisted of positive responses (44 assays) and negative responses (35 assays) to a cytomegalovirus (CMV) pp65 antigen peptide in terms of spot number count. Furthermore, 4 of 35 assays with a negative response based on spot number counting were found to be positive for cytokine activity. Interestingly, the cytokine activity showed similar (5 spot count-positive assays out of 36 cytokine activity-negative assays) results as the spot number data (Figure 4A). As to other peptide-associated ELISPOT responses, positive rates were not so different between spot number and cytokine activity. Similarly, sensitivity and specificity between spot number and cytokine did not show significant difference in various peptide-associated ELISPOT assays (Figure 4B).
Representative images of both spot number and cytokine activity positive cases, spot number-positive only cases, and cytokine activity-positive only cases are shown in Figure 5.
Discussion
The ELISPOT assay is widely available in settings ranging from laboratory experiments to immunotherapy-based clinical trials and is commonly applied to the efficient evaluation of immune responses as an immunological monitoring method. Despite worldwide availability, a high grade of variability in ELISPOT measurement results, such as spot number variation among different laboratories, has been a major problem in clinical settings (9, 10). Recently, as a harmonization program to solve such variability, guidelines for the automated evaluation of ELISPOT assays were established by Janetzki et al. (22-24) in terms of the revision of the protocol and analysis method, resulting in a further reduction in variability and an increase in the reliability of the ELISPOT assay. Additionally, there are four main providers for ELISPOT reader systems: AVEIS, AID (17), Bio-Sys, and Cellular Technology. Cytokine activity is an available measurement parameter on the AID ELISPOT reader, which has not yet been reported in the literature, and is very specific in terms of reflecting features such as spot size and intensity other than spot number.
Additionally, there are two advanced technologies to improve the efficiency of the ELISPOT assay. The first is multicolor-based ELISPOT technology development; an antigen-specific B cell detection system using an antigen-tagged fluorospot assay (25) and a human four-color IFN-γ, IL-2, TNF-α, and granzyme B-specific T cell assay using a fluoro-X software system (26). The second is notable advances in single-cell assays beyond the ELISPOT assay, such as next generation sequencing-based RNA-seq on a single-cell basis. The high sensitivity of the ELISPOT assay has been emphasized thus far; however, novel detection systems using microfluidics or microchamber and RNA-seq-based NGS technologies have been demonstrated to contribute to precise single-cell analysis beyond the capability of the ELISPOT assay (27-29).
In the current study, we focused on a novel ELISPOT parameter, cytokine activity, and compared data for this parameter with commonly available spot number data. Eventually, cytokine activity did not show any advantages in the efficiency to evaluate T cell immune responses than the existing spot number parameter, although cytokine activity is a novel parameter unreported so far. However, the cytokine activity parameter might be helpful in recognizing relatively few and large spots with high intensity and the spot number parameter does not usually contribute to the decision for a positive response. A substantial evaluation of cytokine activity compared with spot number in the future could be an alternative parameter referrable to spot evaluation in the ELISPOT assay.
Acknowledgements
The Authors thank the medical doctors and other staff at the Shizuoka Cancer Center Hospital for collecting blood samples from cancer patients. This work was supported by a grant to Yasuto Akiyama from JSPS KAKENHI (Grant Number 20K07649), Japan.
Footnotes
This article is freely accessible online.
Authors’ Contributions
CM and Yasuto Akiyama participated in the design of the study and drafting of the manuscript and were responsible for completing the study. AI, HM, and Yoshiaki Abe carried out apheresis and were responsible for the immune cell analysis. RK, TA, AK, and KW participated in the design of the experiments and performed the biological assays. SD, KM and NH were responsible for the clinical work of the study and collection of PBMCs and other clinical samples. KY reviewed the manuscript. All Authors read and approved the final draft.
Conflicts of Interest
The Authors declare that they have no competing interests in relation to this study.
- Received June 2, 2021.
- Revision received June 27, 2021.
- Accepted June 28, 2021.
- Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.